Table 1.
Characteristics of randomized, controlled trials of gabapentin, pregabalin, and duloxetine for diabetic peripheral neuropathy and postherpetic neuralgia
| Study ID | Indication | Treatment length in weeks | Sample size | Age in years Mean (SD) | Women No. (%) | Baseline Pain Intensity Score Mean (SD) | Baseline Physical Function Score Mean (SD) | Publication |
|---|---|---|---|---|---|---|---|---|
| Gabapentin | ||||||||
| 945–210 | DPN | 8 | 165 | 53.0 (10.3) | 66 (40.0) | 6.5 (1.5) | 55.7 (27.6) | Backonja (1998)2 |
| 945–224 | DPN | 7 | 243* | 60.5 (10.2) | 103 (42.4) | 6.2 (1.6) | 46.6 (25.9) | Unpublished |
| 945–211 | PHN | 8 | 229 | 71.7 (10.3) | 110 (48.0) | 6.4 (1.7) | 41.3 (27.3) | Rowbotham (1998)39 |
| 945–295 | PHN | 7 | 334 | 73.4 (10.3) | 196 (58.7) | 6.5 (1.6) | 51.2 (29.1) | Rice (2001)36 |
| Pregabalin | ||||||||
| 1008–014 | DPN | 6 | 246 | 57.0 (9.7) | 97 (39.4) | 6.7 (1.5) | 54.7 (26.9) | Richter (2005)37 |
| 1008–029 | DPN | 5 | 260* | 59.5 (10.4) | 101 (38.9) | 6.3 (1.5) | 53.5 (26.8) | Lesser (2004)23 |
| 1008–040 | DPN | 8 | 167** | 61.3 (10.5) | 76 (45.5) | 6.6 (1.6) | 49.8 (25.4) | Unpublished |
| 1008–131 | DPN | 8 | 146 | 59.7 (11.4) | 64 (43.8) | 6.3 (1.6) | 52.1 (26.7) | Rosenstock (2004)38 |
| 1008–149 | DPN | 12 | 384 | 58.6 (11.6) | 174 (45.3) | 6.4 (1.4) | 54.3 (24.4) | Tölle (2008)47 |
| 1008–030 | PHN | 12 | 171* | 70.8 (9.8) | 83 (48.5) | 6.5 (1.6) | 63.4 (26.2) | Unpublished |
| 1008–045 | PHN | 8 | 238 | 72.2 (10.2) | 131 (55.0) | 6.8 (1.6) | 56.1 (27.2) | Sabatowski (2004)40 |
| 1008–127 | PHN | 8 | 173 | 71.5 (10.9) | 92 (53.2) | 6.3 (1.5) | 61.6 (27.0) | Dworkin (2003)11 |
| 1008–196 | PHN | 13 | 368 | 70.7 (10.6) | 200 (54.4) | 6.7 (1.5) | 55.5 (26.7) | van Seventer (2006)55 |
| Duloxetine | ||||||||
| HMAW | DPN | 12 | 342* | 60.1 (11.1) | 136 (39.8) | 5.9 (1.5) | 54.0 (26.1) | Goldstein (2005)17 |
| HMAVa | DPN | 12 | 334 | 60.7 (10.6) | 38.9 (130) | 6.0 (1.5) | 46.0 (26.1) | Wernicke (2006)59 |
*
Study subjects randomized to subtherapeutic dosages (<1200 mg/d of gabapentin, <150 mg/d of pregabalin, and <60 mg/d of duloxetine) were excluded
**
Study subjects randomized to the amitriptyline treatment arm were excluded